Eli Lilly Stock Climbs on Weight-Loss Drug Trial Results

Core Insights - Eli Lilly's shares have increased by 3.7% to $720.07 following positive results from a late-stage trial of its weight-loss pill, orforglipron, which helped type 2 diabetes patients lose 10.5% of their body weight over 72 weeks, paving the way for global approval [1] Group 1 - The stock has been on an upward trend since hitting a 52-week low of $623.78 on August 8, achieving its 10th gain in the last 12 sessions [2] - Despite the recent gains, the shares are still down 24.9% year over year and 7.5% year to date [2] - There has been significant options activity, with 50,000 calls exchanged, which is double the intraday average volume, compared to 20,000 puts [2] Group 2 - The popularity of calls has increased over the last 10 weeks, with a 50-day call/put volume ratio of 1.67, ranking higher than 90% of readings from the past year [3]